
GCTTCACGTTATAAGACGTGACGTAGCGATTTGTAGA



YOUR TRUSTED PARTNER FOR DRUG DEVELOPMENT



#### TATAA at a glance

\*2001





OUR TEAM

>60

employees

>50%

PhDs and Masters

Quality control and QA



WHAT WE'VE DONE

>20


years of work

Multiple

supported drugs

Hundreds

publications



New headquarter with expanded facilities in Gothenburg

ISO17025:2018 accreditation

**GLP/GCP** compliance during 2023

**US** expansion planned



### SPIDIA4P CEN & ISO Standard Documents and EQAs

#### STANDARD

ISO 20395:2019







@ ISO 2019



- Blood Cellular RNA, gDNA, ccfDNA, ccfRNA
- Blood Exosomes / Evs
- Blood Tumor Cells DNA, RNA, staining
- Tissue (FFPE) DNA, RNA, Protein
- Tissue (Frozen) DNA, RNA, Proteins
- Tissue (FFPE) in situ staining
- Fine Needle Aspirates DNA, RNA, Proteins
- Saliva DNA
- Urine & Body Fluids cfDNA
- Metabolomics Urine, Serum, Plasma
- Microbiome Stool, Saliva etc.

Published CEN ⇒ progressing at ISO

**Published ISO** 

Total:22







### SPIDIA4P CEN & ISO Standard Documents and EQAs

Clinical Chemistry 55:4 611-622 (2009)

#### Special Report

### The MIQE Guidelines: Minimum Information for Publication of Quantitative Real-Time PCR Experiments

Stephen A. Bustin, 1\* Vladimir Benes, 2 Jeremy A. Garson, 3,4 Jan Hellemans, 5 Jim Huggett, 6 Mikael Kubista, 7,8 Reinhold Mueller, Tania Nolan, Michael W. Pfaffl, TGregory L. Shipley, 2 Jo Vandesompele,5 and Carl T. Wittwer 13,14

BACKGROUND: Currently, a lack of consensus exists on how best to perform and interpret quantitative realtime PCR (qPCR) experiments. The problem is exacerbated by a lack of sufficient experimental detail in many publications, which impedes a reader's ability to evaluate critically the quality of the results presented or to repeat the experiments.

SUMMARY: Following these guidelines will encourage better experimental practice, allowing more reliable and unequivocal interpretation of qPCR results.

© 2009 American Association for Clinical Chemistry

The fluorescence-based quantitative real-time PCR (qPCR)15 (1-3), with its capacity to detect and mea-



# Bioanalysis during ATMP drug development process

**DISCOVERY** 

**Drug discovery** 

Target identification; Nucleic acid format selection; Vector selection and optimization

PRECLINICAL RESEARCH

ARLY LAT

In vivo/in vitro testing candidate selection

Early studies:

Vector selection.

Dosage determination.

Lead

compound selection.

Late (GLP) studies:

Drug safety

**CLINICAL DEVELOPMENT** 

PHASEI

Safety/Dosage

In limited number of healthy volunteers. Drug safety and dosage.

Efficacy proof of concept (if conducted in patients)

**PHASE II** 

Efficacy/Side effects

Confirmation of efficacy in patients.
Monitoring of side effects.

PHASE III

Efficacy/Adverse events

Superiority over

existing treatments and or placebo. Adverse events. Intended final

drug formulation. Companion diagnostics.

APPROVAL

Post-market surveillance

Long-term safety and efficacy follow-up.

**Biomarkers** 

Pharmacokinetics Biodistribution Pharmacokinetics (PK) / Exposure; Shedding; Pharmacodynamics / Efficacy Biomarkers

Biomarkers

Milestones

IND (US); CTA (EU)

BLA (US); MAA (EU)



# Questions answered by bioanalysis

- How much ATMP is in the body?
- How long does it stay?
- How does the concentration evolve with time?
- In which tissue(s) does the ATMP go?
- How long does it remain?
- How is the ATMP eliminated into the environment through secretions?

- Is the drug active in the body?
- Does it accomplish its intended action?
- Is there a relationship between the drug dose and the concentration of its target?

Pharmacokinetics (PK)

Biodistribution

Shedding

Pharmacodynamics (PD) and Biomarkers

Measure drug

Measure target (direct or not)



## **TATAA's Operating Infrastructure**

10 M€ invested 2021-2023

Robust infrastructure that can handle large and pivotal projects with precision and speed



#### Highest quality hardware

High-throughput NGS, latest digital and quantitative PCR, automated nucleic acid extraction and liquid handlers

#### Most advanced software

Fully integrated Benchling LIMS and ELN solution

#### **Enterprise-grade automation**

Automated liquid handlers standardizing and propelling every workflow we support for clients



# **TATAA's Operating Infrastructure**

Nucleic acids as short as some 15 bases can be analyzed

5

Hemiprobe

microRNAs
siRNA
ASO
FFPE material
Ancient samples




Up to 1000 times more sensitive to detect sequence variations

3

Hemiprobe

ctDNA (cancer)
NIPT
Graft rejection
Forensic samples
Microbiology

# Design and validation of an assay





#### Biomolecular Detection and Quantification

Volume 12, June 2017, Pages 1-6






Research paper

Methods to determine limit of detection and limit of quantification in quantitative real-time PCR (qPCR)

Amin Forootan a, b ス ☒, Robert Sjöback c, Jens Björkman c, Björn Sjögreen b, Lucas Linz d, Mikael Kubista <sup>c, e</sup>


Concentration determined with valide lime




# Example: Adenovirus + vector



Biodistribution 17 tissues 2 time points



Shedding 3 specimens 6 time points







TATAA Biocenter shall be the preferred provider of regulated molecular analysis services to the Pharmaceutical industry



**Genomics – Transcriptomics – Proteomics**